ResMed (NYSE: RMD, ASX: RMD) announced today that it has acquired Mementor (Leipzig) and its digital insomnia therapy in a bid to strengthen its overall sleep portfolio in Germany.
The deal closed yesterday. ResMed did not disclose financial terms. The maker of CPAPs and other respiratory therapy devices was one of the first medical device companies to make the transition into digital, a major trend in the industry.
Mementor is the developer and owner of the digital insomnia therapy app Somnio. ResMed described Somnio as Germany’s first and only permanently approved digital health application (DiGA) in sleep medicine, eligible for reimbursement in Europe’s largest economy. Somnio is also compliant with the EU’s General Data Protection Regulation.
“Mementor is an ideal fit for ResMed Germany and, more important, millions of people across Germany who want to improve their sleep and overall health,” ResMed Germany President Katrin Pucknat said …